Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Immunomedics, Inc." (IMMU) Report Updated: Feb 01, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Immunomedics, Inc." (IMMU)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: SPHS, EXEL, EBS, AVXL

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Immunomedics, Inc."© quotemedia

Company Profile

Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. Its products include epratuzumab, which is in Phase III trials for the treatment of systemic lupus erythematosus in non-Hodgkin lymphoma and acute lymphoblastic leukemia; Yttrium-90-labeled clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that completed a Phase I/II clinical trials; Veltuzumab, a Phase II clinical study completed product for the treatment of patients with non-Hodgkin’s lymphoma and immune thrombocytopenic purpura. The company’s early Phase clinical trial products comprise Milatuzumab, a transmembrane protein product, which is in Phase I study for antibody-drug conjugate therapy; Yttrium-90-labeled epratuzumab tetraxetan, a radiolabeled antibody product candidate, in Phase I/II study for patients with non-Hodgkin lymphoma; Labetuzumab-SN-38, which is in Phase I study in patients with colorectal cancer; hRS7-SN-38, a clinical development stage product for breast, cervix, colon and rectum, lung, pancreas, ovary, and prostate cancers. It also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers; and markets and sells a diagnostic imaging product, LeukoScan to determine infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has license and collaboration agreements with Nycomed GmbH; UCB, S.A.; and GE Healthcare LTD. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Recent News: "Immunomedics, Inc."